I wasn't saying that the indication was anything.
Yes, I do believe they can tell the difference. They aren't determining the risk factor. They are passing on information based on scientific studies. The doctors who ran the studies make the determinations on risk. They provide the links to that research, and even specifically discuss other things you should do if you are concerned, including contacting a genetic counselor.
I didn't believe or not believe, I had gallstones based on the 23andMe report. I believed based on symptoms and a diagnostic ultrasound that showed two golf ball size stones where there should have been none.
Here's the study information they provide with this particular one. There's a lot of information on the page. I don't want to make this post huge by quoting the whole thing. It does include information on the lab that does the testing.
The FDA is pissed that 23andMe is making this information available, where you should normally spend a fortune with doctors, if you can get them to agree to doing genetic testing, to give you the same information.
This SNP is in a gene called ABCG8, which encodes a cholesterol transporter protein. The version of this SNP associated with increased risk for gallstones (C) causes a physical change in the protein that is thought to result in increased cholesterol transport into the biliary ducts and the gallbladder. This may precipitate the formation of gallstones; however, additional studies are needed to elucidate the mechanisms by which this SNP affects gallstone formation. Having two copies of the C version of this SNP confers higher risk than having just one.
Research suggests that the C version of this SNP is also associated with slightly earlier onset of gallstones. There is also some evidence that this SNP may be associated with gallbladder cancer (gallstones are a risk factor for gallbladder cancer), but larger studies are required to verify this.
Multiple studies have confirmed this association in populations with European ancestry. A small Chinese study examined this SNP and found suggestive evidence for the association with gallstones and biliary tract cancer, but more studies are needed to confirm the association in Asian populations. This association has not been studied in populations with African ancestry.
Buch S et al. (2007). "A genome-wide association scan identifies the hepatic cholesterol transporter ABCG8 as a susceptibility factor for human gallstone disease." Nat. Genet. 39(8):995-9.
Stender S et al. (2011)
. "Sterol transporter adenosine triphosphate-binding cassette transporter G8, gallstones, and biliary cancer in 62,000 individuals from the general population." Hepatology 53(2):640-8.
Xu HL et al. (2011). "Cholesterol metabolism gene polymorphisms and the risk of biliary tract cancers and stones: a population-based case-control study in Shanghai, China." Carcinogenesis 32(1):58-62.
The genotyping services of 23andMe are performed in LabCorp's CLIA-certified laboratory. The tests have not been cleared or approved by the FDA but have been analytically validated according to CLIA standards. The information on this page is intended for research and educational purposes only, and is not for diagnostic use.